TEL AVIV, Israel, Dec. 13, 2018 /PRNewswire/ -- Tikcro Technologies Ltd. (OTCQB: TIKRF), a pre-clinical stage developerof antibodies for cancer immune-therapy, today announced that its 2018 Annual General Meeting of Shareholders will be held on Sunday, January 20, 2019 at 11:00 a.m.
The agenda of the meeting is as follows:
Items 1, 3, and 5 require the approval of a simple majority of the shares voted on the matter. Items 2 and 4 require the affirmative vote of a majority of the shares present, in person or by proxy, and voting on the matter, provided that either (i) at least a majority of the shares of non-controlling shareholders or shareholders who do not have a personal interest in the resolution are voted in favor of the proposal (for Item 2, other than a personal interest that is not the result of the shareholder's connections with a controlling shareholder), or (ii) the total number of shares among the shareholders described in section (i) above voted against the proposal does not exceed two percent of the outstanding voting power in the Company. Item 6 will not involve a vote of the shareholders.
Tikcro will send its shareholders of record a proxy statement describing the various matters to be voted upon at the meeting, along with a proxy card enabling them to indicate their vote on each matter.
About Tikcro Technologies:
Tikcro Technologies Ltd. (OTCQB: TIKRF) supports early stage development in growth areas, with a focus on biotechnology projects originated in Israeli academic centers. Tikcro is engaged with development of certain antibodies selected and verified in pre-clinical trials with a focus on antibodies targeting immune modulator pathways for cancer treatment. For more information, visit Tikcro's website at www.tikcro.com.
View original content:http://www.prnewswire.com/news-releases/tikcro-technologies-announces-2018-annual-general-meeting-300765159.html
SOURCE Tikcro Technologies Ltd.
Subscribe to our Free Newsletters!